Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)

NCT04033068 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Zika Virus Infection

Interventions

BIOLOGICAL: Two MV-ZIKA-RSP vaccinations (high dose)
BIOLOGICAL: Two MV-ZIKA-RSP vaccination (low dose)
BIOLOGICAL: One MV-ZIKA-RSP vaccination (high dose) and one placebo
OTHER: Two placebo injection

Sponsor

Themis Bioscience GmbH